Barclays’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-110,018
| Closed | -$8.28M | – | 5342 |
|
|
2022
Q2 | $8.28M | Buy |
110,018
+66,042
| +150% | +$2.93M | 0.01% | 1090 |
|
|
2022
Q1 | $1.18M | Sell |
43,976
-48,109
| -52% | -$1.62M | ﹤0.01% | 2275 |
|
|
2021
Q4 | $4.39M | Buy |
92,085
+71,727
| +352% | +$3.21M | ﹤0.01% | 1807 |
|
|
2021
Q3 | $1.35M | Buy |
20,358
+13,395
| +192% | +$954K | ﹤0.01% | 2603 |
|
|
2021
Q2 | $544K | Sell |
6,963
-35,925
| -84% | -$2.65M | ﹤0.01% | 3038 |
|
|
2021
Q1 | $4.06M | Buy |
42,888
+29,163
| +212% | +$3.47M | ﹤0.01% | 1699 |
|
|
2020
Q4 | $1.67M | Sell |
13,725
-3,394
| -20% | -$372K | ﹤0.01% | 2384 |
|
|
2020
Q3 | $1.5M | Sell |
17,119
-4,300
| -20% | -$300K | ﹤0.01% | 2353 |
|
|
2020
Q2 | $1.38M | Buy |
21,419
+7,040
| +49% | +$406K | ﹤0.01% | 2456 |
|
|
2020
Q1 | $641K | Sell |
14,379
-13,916
| -49% | -$739K | ﹤0.01% | 3379 |
|
|
2019
Q4 | $1.76M | Buy |
28,295
+24,303
| +609% | +$1.16M | ﹤0.01% | 3142 |
|
|
2019
Q3 | $150K | Sell |
3,992
-289
| -7% | -$12.6K | ﹤0.01% | 5170 |
|
|
2019
Q2 | $174K | Buy |
+4,281
| New | +$153K | ﹤0.01% | 5245 |
|
Barclays's TPTX Position: Q3 2022 in Review
Barclays sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 110,018 shares — an estimated $8.28M sold.
Barclays first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $8.28M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.
- Barclays reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- Barclays sold 110,018 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $8.28M.
- Barclays first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
- Barclays's Turning Point Therapeutics, Inc. Common Stock position peaked at $8.28M in Q2 2022.
- 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.
Based on Barclays's 13F filing for Q3 2022, filed 3 Nov 2022.